SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Coca-Cola Company (The). The Group's principal activities are manufacturing, distributing and marketing nonalcoholic beverage concentrates and syrups. The products of the Group include carbonated soft drinks and also various kinds of non carbonated beverages. The Group sells these beverages, concentrates and syrups to bottling and canning operations, distributors, fountain wholesalers and retailers. The other products marketed and distributed by the Group include juice drinks, sports drinks, water products, teas, coffees and other beverage products. The Group also has ownership interests in various canning and bottling operations. The operations of the Group are conducted in the United States, Europe, Eurasia, Middle East, Africa, Latin America and Asia.

Coca-Cola Co

Coca-Colas stronger-than-expected Q2 results and raised full-year outlook, supported by resilient beverage demand and volume growth, have driven a sharp rally and fresh highs. Traders are largely celebrating the earnings momentum and defensive appeal, while others warn the stock looks overvalued or overbought after its run.

Devon Energy Corp. engages in the exploration, development, and production of oil and natural gas properties. It develops and operates Delaware Basin, Eagle Ford, Heavy Oil, Barnett Shale, STACK, and Rockies Oil. The company was founded by J. Larry Nichols and John W. Nichols in 1971 and is headquartered in Oklahoma City, OK.

Devon Energy Corp.

Devons sale of its Eagle Ford assets to Crescent Energy for cash is drawing attention, with traders weighing the proceeds against the assets contribution to production and the companys broader portfolio streamlining. Some are puzzled that the shares are weak despite the sale, while others remain frustrated with DVNs relative performance.

Select Sector SPDR Trust (The) - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

Geopolitical supply concerns tied to the U.S.-Iran conflict, Strait of Hormuz shipping risks and attacks on regional energy infrastructure are keeping energy stocks in focus, alongside tight refined-fuel markets. Traders debate whether those risks will sustain support for XLE or whether diplomacy, recovering flows and profit-taking will unwind the risk premium; some also note the ETF has lagged crude at times.

StablecoinX, Inc. is an infrastructure software and services company. The firm is focusing on supporting the blockchain Ethena. The company was founded on July 7, 2025 and is headquartered in Frisco, TX.

StableCoinX Inc. - Ordinary Shares - Class A

Discussion centers on StablecoinXs large ENA treasury and traders view that USDE trades at a discount to its underlying asset value, making it a proxy for Ethena and broader crypto momentum. Optimism about ENA growth and a proposed buyback framework is tempered by concerns over warrant-related dilution, volatility, and repeated failed rallies.

The mission of the Worldcoin project is to build the world’s largest identity and financial network as a public utility, giving ownership to everyone. A key component of the Worldcoin project is the development of the foundational infrastructure that will be important for a world where AI plays an increasingly large role.  The Worldcoin system revolves around World ID, a privacy-preserving global identity network. World ID enables users to verify their humanness online while maintaining their privacy through zero-knowledge proofs.  Using World ID, individuals will be able to prove that they are a real, unique human to any platform that integrates with the protocol, including to web3 systems, social networking sites, and governmental programs. This will enable fair airdrops or token/NFT sales, provide protection against bots/sybil attacks on social media, and enable the fairer distribution of limited governmental resources. Furthermore, World ID can also enable global democratic processes and novel forms of governance (e.g., via quadratic voting), and it may eventually show a path to AI-funded UBI. The Worldcoin token (WLD), alongside World ID, will let users participate in governing the Worldcoin protocol.   To engage with the Worldcoin protocol, individuals must first download a first wallet app that supports the creation of a World ID. Users visit a physical imaging device called the Orb to get their World ID Orb-verified. Orbs are operated by a network of independent local businesses called Orb Operators. The Orb uses multispectral sensors to verify humanness and uniqueness to issue an Orb-verified World ID, with all images being promptly deleted on-device per default (absent explicit consent to Data Custody). All Orb-verified World IDs holders are entitled to claim recurring grants of free WLD tokens, subject to certain availability restrictions. The WLD token is designed as a utility token with governance properties.

Worldcoin

Worldcoins rally is drawing attention amid the reported Grayscale spot ETF filing and speculation that demand for its proof-of-human identity tools could grow as AI agents spread. Traders are largely bullish on the momentum, while others question the projects fundamentals and warn that volatility and token supply could weigh on the price; ETF approval remains uncertain.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

Golds rebound after a sharp pullback is driving attention, with traders debating whether the bounce marks a durable bottom or a temporary rally. The broader discussion remains split: some expect renewed strength in gold, while others point to elevated Treasury yields and rate-hike concerns as potential headwinds.

Zoracles

Renewed price and volume spikes have drawn attention to ZORA, prompting speculation about another momentum run or short squeeze; traders disagree over whether the rallies can hold, with some warning they may fade as before. Some also discuss Zoras expansion into Solana-based attention markets, while questioning whether it benefits ZORA token holders.

XPeng, Inc. is a global physical AI company, which engages in bringing artificial intelligence into the physical world to reshape future mobility and smart living. It developed a full-stack physical AI architecture spanning Turing AI chips, world foundation models, and integrated software and hardware applications. The firm's product portfolio includes smart EVs, robotaxis, and humanoid robots. The company's sales and services drives continuous technological innovation and fosters an open physical AI ecosystem, making life smarter, safer, and better for users worldwide. XPeng, Inc. was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPeng is drawing attention amid a prolonged selloff in Chinese EV stocks, with traders focused on weak demand and profitability concerns and recent analyst downgrades. Bulls point to technology licensing, international expansion, autonomous driving and robotics as potential growth drivers, while skeptics question whether those initiatives can offset pressure in the core auto business.

Affirm Holdings, Inc. operates a platform for digital and mobile-first commerce. Its platform consists of three core elements: a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The company was founded by Max R. Levchin in 2012 and is headquartered in San Francisco, CA.

Affirm Holdings Inc - Ordinary Shares - Class A

Affirm Holdings Inc

Affirms rebound and push through recent resistance have traders focused on whether the technical move can hold, with bullish calls for further gains countered by warnings of a pullback. The discussion also reflects ongoing debate over growth and profitability versus higher-rate and consumer-credit risks for BNPL lenders.

X-Energy, Inc. engages in the development of advanced small modular nuclear reactors and fuel technology for clean energy generation. Its solutions include Xe-100 and TRISO-X. The company was founded by Kam Ghaffarian and Eben Mulder in 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-Energy Inc

XE is drawing attention for its steep post-IPO selloff, which traders attribute in part to a bearish analyst downgrade and selling pressure after the lockup expiration. Bulls are buying dips on Amazons backing, federal support and the AI-related nuclear-power opportunity, while bears point to the companys early stage and long path to commercialization.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

EXCLUSIVE: GT Biopharma Achieves Development Milestone for Human Trial for Novel Blood Cancer Therapy

GT Biopharma secures FDA IND clearance for GTB-5550, advancing its TriKE therapy into Phase 1 clinical trials for multiple myeloma.read more...

A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs

A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs PR Newswire SAN FRANCISCO, July 6, 2026 Issued on...

A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs

A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs PR Newswire NEW YORK, June 30, 2026 Issued on behalf of GT Biopharma, Inc.GT...

A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company

A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company PR Newswire SAN FRANCISCO, June 2, 2026 Equity Insider News CommentaryIssued on behalf of GT Biopharma, Inc. (NASDAQ: GTBP)SAN FRANCISCO, June 2...

EXCLUSIVE: GT Biopharma Sees Faster Discovery, Productivity Following AI Technology Rollout

GT Biopharma says AI-driven drug discovery tools are accelerating pipeline development and may yield new pre-IND candidates by 2027.read more...

The $13 Million Company Teaching the Immune System to Hunt Cancer

The $13 Million Company Teaching the Immune System to Hunt Cancer The $13 Million Company Teaching the Immune System to Hunt Cancer PR Newswire NEW YORK, May 29, 2026 Issued on behalf of GT Biopharma, Inc. (NASDAQ: GTBP)Three drugs in human trials. A platform licensed from one of the world's top...

Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes

Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes PR Newswire SAN FRANCISCO, May 19, 2026 Equity Insider News...

B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic

B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic PR Newswire SAN FRANCISCO, May 18, 2026 Issued on behalf of GT Biopharma, Inc.SAN FRANCISCO, May 18, 2026 /PRNewswire/ -- USA News Group...

Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase

Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth...

EXCLUSIVE: GT Biopharma Begins Testing Of Lead Solid Tumor Drug Candidate Across Multiple Cancer Types

GT Biopharma doses first patient in Phase 1 GTB-5550 trial targeting B7-H3-positive solid tumors with subcutaneous TriKE therapy.read more...

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary TriKE and Dual Targeting TriKE platforms. Its product candidates include GTB-3650, a CD33-targeted therapy for relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome, and GTB-5550, a B7-H3-targeted therapy for solid tumors. The company was founded in 1965 and is headquartered in San Francisco, CA.

GT Biopharma Inc

GT Biopharma Stock Logs Best Session In Over 9 Months On Promising Cancer Trial Data; Retail Eyes Double-Digit Rally

Equity

Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Stocktwits

Stocktwits Polls

$GTBP Reverse split then paid promotion, Don’t be looking for a chair when the music stops.  I do hope they have a legitimate product that helps with curing cancer just be careful with the manipulation

Lucas Skygihhilfe

$GTBP ha, companies are announcing offerings on Friday afternoons, theirs is the 5th one in the last hour

B Morgan

$GTBP - pre-marker saw this go to $13+, should easily find some balance and get back in the $10-11 range for a bounce once short sellers dry up by end of day

Ricky

$GTBP GT Biopharma Announces Potential New Indication for GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager, for Multiple Myeloma

Day Trader

Some smallcaps with more than 20% gain yesterday, but without a big drop in the last month:  
$GTBP : up more than 50% from 30 days ago.  
$VNCE : up about 25% in a month.  
MWC stable for more than a month, consolidated and yesterday started. 
$AIXC +70% in a month, let's see what it can do today. 
$HMR great pick of the 1st semester, more than 100% from last spring.

Martha Varias

$GTBP low vol but big day. Congrats to my trading peers for making bank.  
 
Now, im getting slowly into NCRA, sub 2m float with no short share left + 300% ctb + AI + Ties to Micron + News friendly + Known runner + bullish tape

BlakeCapital

Wow, Big traders calling MLEC for a squeeze!    
   
Looks like he is right again, Loads of bulls shifting to MLEC now!  🚀    
   
The next parabolic low float runner?   
   
All eyes on MLEC in to close here $GTBP $SWRD :L

Feed

News

Sentiment

Earnings

Fundamentals

Info

GTBP GT Biopharma Inc

Fundamentals

Latest GTBP News